Dr. Geffner leads PNH clinical development and medical affairs for all Achillion programs. Prior to Achillion, Dr. Geffner spent 15 years in various positions of increasing responsibility Schering-Plough/Merck including Clinical Development, Clinical Operations, and Medical Affairs.
Dr. Geffner was a key member of the Peg-Intron NDA team and led the first phase 2 clinical trial for Boceprevir at Schering-Plough. He made significant contributions to the integration process when Schering Plough acquired Organon Biosciences and integrated their portfolio and team into his clinical operations team. The structure launched by Dr. Geffner in North America was then adapted and launched worldwide at Schering Plough and he assisted in rolling out this structure around the globe. He also led Clinical Operations for Europe II, Middle East and Africa, which contained approximately 70 countries. He continued in an operations capacity when Schering-Plough was acquired by Merck and led clinical operations for North America at Merck and had a team that covered all phases of research, with well over 100 clinical trials in the portfolio and a team size that exceeded 400 individuals. In his most recent role as Executive Director of Medical Affairs for Merck Dr. Geffner led the HIV, HCV, antibiotic, antifungal, and anesthesia/surgical portfolios and served as the integration lead for the acquisition of Cubist Pharmaceuticals.
Dr. Geffner is a US licensed physician with dual board certification from the American Board of Pediatrics and The American Board of Psychiatry and Neurology with special competency in Child Neurology. He is a Graduate of Albany Medical College and holds an MBA from Fairleigh Dickinson University.